ALBO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALBO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).
Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.
Albireo Pharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.
For the Biotechnology subindustry, Albireo Pharma's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Albireo Pharma's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:
* The bar in red indicates where Albireo Pharma's Margin of Safety % (DCF Dividends Based) falls into.
Thank you for viewing the detailed overview of Albireo Pharma's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.
Harford Simon N.r. | officer: CFO and Treasurer | AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
Pamela Stephenson | officer: Chief Commercial Officer | C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
Martha J. Carter | officer: Chief Regulatory Officer | C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960 |
Jan Mattsson | officer: Chief Operating Officer | C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109 |
Cooper Ronald Harold Wilfred | director, officer: President and CEO | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
Michelle Graham | officer: Chief Human Resources Officer | 10000 WEHRLE DRIVE, CLARENCE NY 14031 |
Jason Duncan | officer: General Counsel | C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109 |
Paul Streck | officer: Chief Medical Officer | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Craig C. Hopkinson | director | 852 WINTER STREET, WALTHAM MA 02451 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Susan Alesina | director | C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109 |
Habib J Dable | director | C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
Patrick Taylor Horn | officer: Chief Medical Officer | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By sperokesalga sperokesalga • 02-08-2023
By PRNewswire PRNewswire • 01-23-2023
By Stock market mentor Stock market mentor • 02-03-2023
By Value_Insider Value_Insider • 11-07-2022
By PRNewswire PRNewswire • 01-10-2023
By Stock market mentor Stock market mentor • 02-08-2023
By Business Wire Business Wire • 01-11-2023
By Business Wire Business Wire • 01-09-2023
By PRNewswire PRNewswire • 02-07-2023
By sperokesalga sperokesalga • 02-14-2023